Product characteristics
❖ Rapid detection of the new SARS-CoV-2 (Covid-19) in approximately 1 hour
❖ Without additional specialized instrumentation; tests performed on standard qPCR machines
❖ Low sample volume requirements
❖ Internal positive control to confirm RNA quality is acceptable for diagnostic tests
❖ Stable at -20 ° C for up to 18 months
Order information
1. Product Name: AMD Human SARS-CoV-2 Direct qPCR Detection Kit
- Technology: One Step Real-Time PCR
- Package: 100 Reactions
- Catalog No.: KD145906D-100
2. Product Name: AMD Human SARS-CoV-2 Direct qPCR Detection Kit
- Technology: One Step Real-Time PCR
- Package: 600 Reactions
- Catalog No.: KD145906D-600
Overview:
The new SARS-CoV-2 (COVID-19) is a severe acute respiratory syndrome coronavirus that is responsible for a respiratory illness that was first detected in Wuhan city, Hubei province, China, and later caused a pandemic. world. The virus is contagious and is transmitted mainly through the exchange of droplets of mucus that are expelled when sneezing or coughing. This outbreak is an important reminder that the global community must strengthen national and international programs for the detection and response to future disease outbreaks.
Product Details:
The Zena Max SARS-CoV-2 Direct qPCR Assay System is a real-time PCR that enables direct amplification of COVID-19 infection in human specimens such as nasopharyngeal swabs (NPS), nasal swabs, nasal lavage or aspiration or bronchoalveolar lavage (BAL) using one-step RT-qPCR by reverse transcription of a genomic RNA target to cDNA, followed by assay target amplification and detection by qPCR hydrolysis probe method. The assay consists of a forward primer, a reverse primer and a probe labelled with the 5 ‘FAM ™ reporter dye and ROX with a 3’ quencher.
As the new target cDNA strand is synthesized, the tightly bound probe is cleaved by the 5 ‘to 3’ exonuclease activity of Taq polymerase which releases the fluorescent reporter from the quencher and substantially increases the fluorescent signal. The point at which fluorescence becomes detectable above the background, the quantitation cycle (Cq), is proportional to the amount of target present in the sample.
The SARS CoV-2 (2019-nCoV) genomes are designed for the in vitro detection of SARS COV-2 genomes. The lower the Cq, the greater the amount of target present. However, if SARS-CoV2 (COVID-19) is not present, a FAM or ROX signal will not occur. An internal positive control assay is provided to assess the quality of the sample and the effect of any PCR inhibitors that may be present.
This assay contains two primers and a HEX-labeled probe, designed for a highly conserved region of human RNA and a positive signal indicates that the quality of the RNA in the sample is acceptable for diagnostic testing. Both assays are incorporated into a ready-to-use PCR master mix that uses hot start technology, minimizing nonspecific reactions and ensuring maximum sensitivity.
The Zena Max COVID-19 Direct qPCR Kit is sensitive to a minimum of 10 copies per reaction. In silico analytical specificity shows that the AMD SARS-CoV-2 assays have 100% sequence identity with 769 of the 773 (99.4%) SARS-CoV-2 genomes available in public databases.